Gouda Z, Thomson D M
Division of Clinical Immunology and Allergy, Montreal General Hospital, Quebec, Canada.
Jpn J Cancer Res. 1988 Apr;79(4):529-37. doi: 10.1111/j.1349-7006.1988.tb01623.x.
In vitro cell-mediated immunity was assayed by leukocyte adherence inhibition (LAI) to determine the extent of autosensitization to myelin basic protein (MBP). Leukocytes from 123 cancer patients, 16 patients freed of cancer, 135 patients with benign disease, and 26 patients with destruction of nervous parenchyma were tested. Most patients with cancer reacted to MBP: 92%, 93%, 82%, 78%, 75% and 62% for pancreatic, colonic, esophageal, lung, ovarian and breast. Few patients with benign diseases reacted to MBP. Patients with multiple sclerosis (MS) were sensitized to MBP, but patients with other nervous tissue injury did not react to MBP. Cancer patients did not remain sensitized to MBP once they were freed of their cancer. The LAI assay is a straightforward method of measuring cellular autosensitivity to MBP. In the population of patients tested, autosensitivity to MBP was confined, except for MS, principally to cancer patients.
通过白细胞黏附抑制（LAI）测定体外细胞介导的免疫，以确定对髓鞘碱性蛋白（MBP）自身致敏的程度。对123例癌症患者、16例癌症已治愈患者、135例良性疾病患者和26例神经实质破坏患者的白细胞进行了检测。大多数癌症患者对MBP有反应：胰腺癌、结肠癌、食管癌、肺癌、卵巢癌和乳腺癌患者的反应率分别为92%、93%、82%、78%、75%和62%。很少有良性疾病患者对MBP有反应。多发性硬化症（MS）患者对MBP致敏，但其他神经组织损伤患者对MBP无反应。癌症患者一旦治愈癌症，就不再对MBP致敏。LAI测定是一种测量细胞对MBP自身敏感性的直接方法。在受试患者群体中，除MS外，对MBP的自身敏感性主要局限于癌症患者。
